Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Persistent mutation burden drives sustained anti-tumor immune responses.
Niknafs N, Balan A, Cherry C, Hummelink K, Monkhorst K, Shao XM, Belcaid Z, Marrone KA, Murray J, Smith KN, Levy B, Feliciano J, Hann CL, Lam V, Pardoll DM, Karchin R, Seiwert TY, Brahmer JR, Forde PM, Velculescu VE, Anagnostou V. Niknafs N, et al. Among authors: seiwert ty. Nat Med. 2023 Feb;29(2):440-449. doi: 10.1038/s41591-022-02163-w. Epub 2023 Jan 26. Nat Med. 2023. PMID: 36702947 Free PMC article.
Neoadjuvant chemotherapy for advanced oral cavity cancer.
Yaniv D, Seiwert TY, Margalit DN, Williams MD, Barbon CEA, Largo RD, Smith JA, Gross ND. Yaniv D, et al. Among authors: seiwert ty. CA Cancer J Clin. 2024 May-Jun;74(3):213-223. doi: 10.3322/caac.21829. Epub 2024 Feb 8. CA Cancer J Clin. 2024. PMID: 38329372 Free article. No abstract available.
International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancers.
Liem X, de Baère T, Vivar OI, Seiwert TY, Shen C, Pápai Z, Moreno V, Takácsi-Nagy Z, Helfferich F, Thariat J, Gooi Z, Yom SS, Bossi P, Ferris RL, Hackman TG, Le Tourneau C, Rodriguez J, Hoffmann C. Liem X, et al. Among authors: seiwert ty. Head Neck. 2024 Jun;46(6):1253-1262. doi: 10.1002/hed.27739. Epub 2024 Apr 10. Head Neck. 2024. PMID: 38600434
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Seiwert TY, Wildsmith S, Fayette J, Harrington K, Gillison M, Ahn MJ, Takahashi S, Weiss J, Machiels JP, Baxi S, Baker V, Evans B, Morsli N, Jill Walker, Real K, L'Hernault A, Psyrri A. Seiwert TY, et al. Cancer Immunol Immunother. 2024 Mar 2;73(4):70. doi: 10.1007/s00262-024-03643-3. Cancer Immunol Immunother. 2024. PMID: 38430375 Free PMC article.
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Rosenberg AJ, Liao CY, Karrison T, de Souza JA, Worden FP, Libao B, Krzyzanowska MK, Hayes DN, Winquist E, Saloura V, Prescott K, Villaflor VM, Seiwert TY, Schechter RB, Stadler WM, Cohen EEW, Vokes EE. Rosenberg AJ, et al. Among authors: seiwert ty. Ann Oncol. 2023 Aug;34(8):714-722. doi: 10.1016/j.annonc.2023.05.002. Epub 2023 May 13. Ann Oncol. 2023. PMID: 37182801 Clinical Trial.
110 results